Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Apr 13, 2022 4:19pm
189 Views
Post# 34601716

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:$tltff The FDA wants an option that has rates better then

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:$tltff The FDA wants an option that has rates better thenThe updated protocol/bladder volume calculation (although not perfect) should help maximize the exposure/surface area of the inner bladder wall.  However, "old" bladders tend to be less expansile & this will pose an ongoing challenge imo.  I imagine over time there will be additional modifications made to help improve dosing, such as what enrique suggested (changing a patient's body position to possibly allow for more even drug distribution...this is done intraoperatively to maximize chemo treatment of certain intra-abdominal tumors that affect the inner lining of the abdomen or peritoneum).  JMO.
<< Previous
Bullboard Posts
Next >>